PYRANS FOR USE IN THE TREATMENT OF INFECTION

WIPO Patent Application WO/2006/003458

A1

There is provided a novel compound of the general formula (I), in which each R is hydrogen, aryl, C_1-6 alkyl, trialkylsilyl, or acyl, each R¹ is selected from hydroxy, C_1-6 alkoxy and acyloxy; each R² is H, C_1-4 alkyl, trialkylsilyl or acyl; R³ is H or Me; and n is 0 to 5 any of the alkyl groups including alkyl groups in alkoxy, acyl and acyloxy groups which may be substituted by aryl, C_1-4 alkyl, C_1-4 alkoxy, hydroxyl, trialkylsiloxy or acyloxy groups. The compound is an analogue of epigalcatechin galate or epicatechin galate, with an amide bonding placed of the natural ester bond, with resistance to hydrolysis by esterase enzymes. The compounds may be used to modulate the resistance to β-lactam antibiotics of various infections, especially methicillin resistant staphylococcus aureus (MRSA). Pharmaceutical compositions containing the novel compounds and combinations of the novel compounds and β-lactam antibiotics are described.

Anderson, James Clive (Department of Chemistry, University of Nottingham, Nottingham NG7 2RD, GB)
Headley, Catherine (Department of Chemistry, University of Nottingham, Nottingham NG7 2RD, GB)
Stapleton, Paul Darren (School of Pharmacy, University of London 29/39 Brunswick Square, London WC1N 1AX, GB)
Taylor, Peter William (School of Pharmacy, University of London 29/39 Brunswick Square, London WC1N 1AX, GB)

PCT/GB2005/002670

January 12, 2006

July 06, 2005

Click for automatic bibliography generation  

SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (29/39 Brunswick Square, London WC1N 1AX, GB)
Anderson, James Clive (Department of Chemistry, University of Nottingham, Nottingham NG7 2RD, GB)
Headley, Catherine (Department of Chemistry, University of Nottingham, Nottingham NG7 2RD, GB)
Stapleton, Paul Darren (School of Pharmacy, University of London 29/39 Brunswick Square, London WC1N 1AX, GB)
Taylor, Peter William (School of Pharmacy, University of London 29/39 Brunswick Square, London WC1N 1AX, GB)

C07D311/60; C07D311/62; (IPC1-7): C07D311/60; C07D311/62; A61K31/352; A61P31/04

GILL JENNINGS & EVERY LLP (Brodgate House, 7 Eldon Street, London EC2M 7LH, GB)

View/Download PDF      PDF Help

CLAIMS

1.

A compound of the general formula I in which each R is hydrogen, aryl, C16 alkyl, trialkylsilyl, or acyl, the or each R1 is selected from hydroxy, C16 alkoxy and acyloxy; each R2 is H, C14 alkyl, trialkylsilyl or acyl; R3 is H or Me; and n is 0 to 5 in which any of the alkyl groups including alkyl groups in alkoxy, acyl and acyloxy groups may be substituted by aryl, C14 alkyl, C14 alkoxy, hydroxyl, trialkylsiloxy or acyloxy groups.

2.	A compound according to claim 1 in which each R1 is OH.

3.	A compound according to claim 1 or claim 2 in which n is 2 or.

4.	A compound according to any preceding claim in which each R is H.

5.	A compound according to any preceding claim in which each R2 is H.

6.	A compound according to any preceding claim in which R3 is H.

7.	A compound according to any preceding claim which has the structure Ia or Ib.

8.	Use of a compound according to claims 2, 4 and 5 in the manufacture of a composition for use in the treatment of methicillin resistant S. aureus infection.

9.	Use according to claim 8 in which a βlactam antibiotic is also administered in the treatment.

10.	A composition comprising a compound as defined in claim 8 and a carrier.

11.	A pharmaceutical composition comprising a compound as defined in claim 8 and a pharmaceutical excipient.

12.	A composition according to claim 11 further comprising a βlactam antibiotic.

13.

A method of synthesising an amide product in which an amine compound of the formula Il in which R3 is H or Me; n is 0 to 5 the or each R4 is a hydroxyl protecting group; and each R5 is a hydroxyl protecting group is reacted with an acylating compound of the formula III in which each R is a hydroxyl protecting group and is a leaving group to produce an amide compound of the formula IV in which R3, R4, R5, R6 and n have the same meanings as in the starting compounds.

14.	A method according to claim 13 in which R3 is hydrogen and in which the compound of formula IV is methylated with a methylating reagent to replace the hydrogen atom which is R3 by a methyl group, to produce a final product compound having general formula IV in which R3 is methyl.

15.	A method according to claim 13 or claim 14 in which the compound of formula IV is subjected to one or more hydroxyl deprotection steps in which each group R4, each group R5 and each group R6 is replaced by hydrogen.

16.

A method according to any of claims 13 to 15 including the preliminary step of producing the amine compound of the formula Il by reductive amination of a compound of the formula V in which the groups R4 and R5 and n have the same meanings as in the compound Il with an amine reagent of general formula Vl H,NR7 Vl in which R7 is hydrogen an alkyl group or an aralkyl group and a reducing agent to produce a compound of formula VII in which R4, R5, R7 and n have the same meanings as in the respective starting compounds.

17.

A method according to claim 16 in which R7 in the compound of formula VII produced in the reaction with amine reagent and reducing agent in the compound of formula VII produced in the reaction with amine reagent and reducing agent is different to R3 in the amine compound which is reacted with the acylating compound and which includes the step of replacing the groups R7 of the compound of the formula VII by a group R3 which is a hydrogen atom or a methyl group prior to the reaction with acylating compound.

18.	A method according to claim 17 in which R7 is benzyl.

19.	A method according to any of claims 16 to 18 which includes a preliminary step in which the compound of formula V is produced by oxidation of an alcohol compound of the formula VIII in which R4, R5 and n have the same meanings as in the compound of formula V using an oxidising agent.

20.	A method according to claim 19 in which the oxidising agent is Dess Martin periodinane.

21.	A compound of formula IX in which n is 0 to 5; each R8 is hydrogen or a hydroxyl protecting group; and each R9 is hydrogen or a hydroxyl protecting group.

22.	A method of synthesising a compound according to claim 21 by oxidation of an alcohol compound of the formula Xl in which R8 and R9 are hydroxyl protecting groups and n is 0 to 5 using an oxidising agent, preferably DessMartin periodinane.

23.	A compound of formula X in which n is 0 to 5; each R10 is hydrogen or a hydroxyl protecting group; each R11 is hydrogen or a hydroxyl protecting group; and R12 is hydrogen, methyl or an amino protecting group.

24.	A compound according to claim 23 in which each R11 and each R12 is the same and is a hydroxyl protecting group and R12 is benzyl.

25.

A method of synthesising a compound according to claim 23 by reductive amination of a compound of the formula V in which the groups R4 and R5 are hydroxyl protecting groups and n is 0 to 5, with an amine reagent of general formula Vl H2NR7 Vl in which R7 is hydrogen an alkyl group or an aralkyl group and a reducing agent to produce a compound of formula VII in which R4, R5, R7 and n have the same meanings as in the respective starting compounds.

PYRANS FOR USE IN THE TREATMENT OF INFECTION The present invention relates to novel compounds of use in treatment of methicillin resistant Staphylococcus aureus (MRSA) infection in conjunction with β-lactam antibiotics. S. aureus is one of the major causes of both nosocomial and community-acquired infections worldwide. The use and overuse of β-lactam agents and other antibiotics has resulted in intense selective pressure on bacterial populations and led to the emergence of multi-drug resistant bacteria that threaten our ability to treat serious infections, particularly in hospitals. Over the last 15 years there has been a steady rise in the incidence of methicillin-resistant S. aureus (MRSA) and the latest figures from the PHLS Communicable Disease Surveillance Centre indicate that, in England and Wales, 42% of S. aureus isolates are now resistant to this agent. Staphylococci show a strong tendency to accumulate antibiotic resistant genes and the majority of MRSA isolates are now resistant to a range of antibiotics. Ominously, MRSA strains carrying the enterococcal vanA gene complex and expressing high-level resistance to vancomycin have recently been identified in clinical specimens from two unrelated cases. The introduction of Synercid and Linezolid and the anticipation of a third agent with activity against MRSA (Daptomycin) supplements the anti-MRSA armamentarium but there remains an urgent need for new treatments for these infections, in particular agents that suppress or abrogate the emergence of resistance. We are examining the therapeutic potential of agents that do not directly kill the target bacterial population but modify them to produce a "less fit" phenotype with reduced capacity to survive at the site of infection. There are conceptual reasons to suppose that this approach will result in less selective pressure on the bacteria and delay the emergence of resistant genotypes. Polyphenol ic components extracted from Japanese green tea (Camellia sinensis) possessed a number of activities against methicillin resistant S. aureus (MRSA) (Yam, T.S. et al 1997; Yam, T.S. et al 1998; Stapleton, P. D. et al (2002)) in addition to weak direct antibacterial activity, extracts were able to suppress the activity of staphylococcal β-lactamases. In addition, at subinhibitory concentrations they were also able to sensitise MRSA strains to methicillin and other semi-synthetic β-lactam antibiotics; this effect was marked and reduced the Minimum Inhibitory Concentration (MIC) of test strains from full resistance to below the antibiotic break point. Initial observations were made using aqueous extracts of green tea; partition chromatography was then used to fractionate the material (Yam, T. S. et al 1997). Activity was confined to one fraction that was enriched for the compound epigallocatechin gallate ECg, an abundant polyphenols component of green tea, but other constituents were present in small amounts. Unfortunately, epicatechin gallate cannot be widely administered because it is broken down by esterases in the body to the inactive products, epicatechin and gallic acid (Stapleton, P. D. et al (2002)). It has been observed that MRSA grown in the presence of sub¬ inhibitory concentrations of tea extracts have thickened cell walls and form pseudomulticellular aggregates (Hamilton-Miller, J. MT et al (1999)). Green tea administered as a spray has been successfully used in the treatment of an MRSA infection of the trachea (windpipe) (Yamashita, S. et al (2001 )). Stapleton et al (2004) describe some investigations into the molecular mechanism of β-lactam sensitisation to establish a basis for the rational selection of pharmacologically acceptable molecules, investigated structure- activity relationships (SAR) to identify pharmacophores within active molecules. The capacity of catechins and gallates to modulate β-lactam resistance was evaluated by testing the compound at a fixed concentration in combination with oxacillin. Modulating activity was defined as a greater than two-fold reduction in the MIC of a β-lactam when tested in combination with a fixed sub-inhibitory concentration of the test compound. ECg converted MRSA strain BB568, which has a MIC of 256 mg/L for oxacillin, to the fully drug sensitive phenotype (1 mg/L) and below the breakpoint. EGCg reduced the MIC of BB568 to 8 mg/L; epicatechin (EC) and epigallocatechin (EGC), the two most abundant non-gallyl catechins in tea, were inactive in the combination assay. These compounds were tested against a comprehensive collection of 40 MRSA strains isolated from a variety of countries; epidemic MRSA strains from the UK were included. With all strains, ECg reduced the MIC values to the susceptibility breakpoint or below. The physical properties of ECg and EGCg suggest these molecules have the capacity to intercalate into target membrane bilayers and perturb the function of key membrane-associated proteins in peptidoglycan synthesis, such as femA, femB and mecA gene products; it is highly likely that such an interaction would also reduce or prevent the transport of proteins not essential for cell viability across the bilayer. Japanese workers have shown that catechins are able to bind to artificial lipid bilayers (Nakayama, T. et al 1998, Hashimoto, T. et al 1999) and recent work (Kajiya, K. et al 2001 and Kajiya, K. et al 2002) shows that binding affinities appear to correlate with the bioactivity of catechins in our assay. Thus, ECg has a greater propensity to intercalate into the phospholipid palisade than EGCg, catechin or EC (Cartula, N. et al 2003). Binding has been shown to be dependent upon the number of hydroxyl groups on the B-ring (see Fig. 1 for structure); catechins with two hydroxyl groups, such as ECg, have a greater membrane binding capacity than those with three hydroxyl groups, such as EGCg (Kajiya, K. et al 2001). The binding of ECg to liposomes is enhanced in the presence of EC (Kajiya, K. et al 2002). According to the invention there is provided a new compound of the general formula I

in which each R is hydrogen, aryl, C1-6 alkyl, trialkylsilyl, or acyl, the or each R1 is selected from hydroxy, C1-6 alkoxy and acyloxy; each R2 is H, C1-4 alkyl, trialkylsilyl or acyl; R3 is H or Me; and n is 0 to 5 in which any of the alkyl groups including alkyl groups in alkoxy, acyl and acyloxy groups may be substituted by aryl, C1-4 alkyl, C1-4 alkoxy, hydroxyl, trialkylsiloxy or acyloxy groups. Preferably n is 2 or 3. Compounds of the general formula I wherein each group R1 is hydroxy, n is 3 and each group R and R2 is hydrogen, are analogues of the naturally occurring compound ECg, wherein the ester linkage is replaced by an amide linkage. Such compounds have similar activity to the corresponding ester and are less susceptible of esterase hydrolysis. Accordingly the present invention provides novel compositions comprising such compounds, and a carrier, for instance pharmaceutical compositions which comprise a pharmaceutically acceptable excipient. The invention also provides such compounds for use in a method of treatment of a human or animal, usually a method in which the compound is administered in conjunction with a β-lactam antibiotic to treat a S. aureus infection. Compositions may, conveniently, contain both the novel compound and the antibiotic. The compounds are believed to have activity in reducing the β-lactam resistance of infections when administered at a level to give local concentrations of around 2 to 25 mg/l. The compounds may be administrable orally but preferably are administered systemically, preferably parenterally, or locally, for instance topically. The compositions are thus adapted for the appropriate mode of administration. A suitable daily dosage for an adult human patient may be in the range 50 to 100 mg/day. It may be necessary to administer the daily dosage in several dosage units, for instance at intermittent periods during the day. Compounds in which any of the groups R2 or R represent other than hydrogen may be precursors for the active compounds. It is possible that these precursors may be incorporated into compositions for administration, provided they are capable of being metabolised in the body to form the active compounds. Preferably, however, the precursors are reacted, to generate hydroxyl groups from the protected hydroxyl groups represented by OR2 and OR. The protecting groups, that is the groups R and R2, may be the same or different to one another. Usually all groups R2 are the same as one another and all groups R are the same as one another. Preferably the groups R2 are the same as the groups R. Usually the protecting groups are reacted onto the hydroxyl groups of a compound already comprising the two rings (the B and D rings) in its skeleton. Consequently the same protecting groups will be generated. By having the same protecting groups, whether or not derived by reacting a compound having a skeleton including both rings, or by conjugating together compounds having one or the other ring, deprotection can take place in a convenient and simple step involving a single deprotection step. Where the groups R2 and groups R are the same, the same deprotection step will remove all protecting groups. Of course a person skilled in the art would be able to devise sequential deprotection steps with different reagents where the groups are different. Suitable hydroxyl protecting groups are tertiary butyldimethylsilyl (TBS), acyl, alkyl or aralkyl, such as benzyl or tertiary butyl. In general formula I, in the B ring (the upper ring), the substituents R1 preferably include at least one group para to the attachment to the C ring. The other group is preferably ortho to this group. Where there are three substituents (that is n is 3), the substituents are preferably para and meta to the attachment. Preferably such substituents are hydroxyl or, for precursor compounds, protected hydroxyl. Compounds in which n is 2 are believed to have better membrane binding properties than those in which n is 3. With regard to the stereo chemistry of the compounds, it is preferred that the compound be in one of the forms Ia or Ib

The stereo isomers with structure Ib are believed to have optimal activity. According to the present invention there is also provided a method for synthesising the novel compounds. In the new method an amine compound of the formula Il

in which R3 is H or Me; n is 0 to 5; each R4 is a hydroxyl protecting group; and each R5 is a hydroxyl protecting group is reacted with an acylating compound of the formula

in which each R6 is a hydroxyl protecting group and L is a leaving group to produce an amide compound of the formula IV

in which R3, R4, R5, R6 and n have the same meanings as in the starting compounds. Where the desired final product has a methyl substituent as a group R3, this may be added by a derivatisation reaction carried out after formation of the amide bond, by reaction of a compound of the formula IV in which R3 is hydrogen with a methylating reagent such as methyl halide. The method of the invention may include deprotection steps following the formation of the amide bond, in which groups R5, R4 and R6 are removed and replaced by hydrogen. The starting amine is also a new compound. According to a further aspect of the invention such novel compounds are defined by formula X

in which n is 0 to 5; each R10 is hydrogen or a hydroxyl protecting group; each R11 is hydrogen or a hydroxyl protecting group; and R12 is hydrogen, methyl or an amino protecting group. In compounds of the formula X, the hydroxyl protecting groups may be any of those defined above with reference to compounds of the formula I. The amine protecting groups may be any of those conventionally used in synthetic peptide chemistry, for instance benzyloxycarbonyl, butyloxycarbonyl, fluorenyl-9-methoxy-carbonyl, 2-[biphenylyl-(4)]-propyl-2- oxycarbonyl-, dinitrophenyl, tosyl, alkyl or benzyl. Preferably R12 is benzyl. The amine compound, either the starting material of the formula Il or the novel compound of the formula VII, may be made in a preliminary step by reductive amination of a compound of the formula V

in which the groups R4 and R5 are hydroxyl protecting groups and n is 0 to 5, with an amine reagent of general formula Vl H,NR7 Vl in which R7 is hydrogen an alkyl group or an aralkyl group and a reducing agent to produce a compound of formula VII

in which R4, R5, R7 and n have the same meanings as in the respective starting compounds. The ketone compound of the formula V may be a novel compound. According to a further aspect of the invention, there is claimed novel compounds compound of formula IX

in which n is 0 to 5; each R8 is hydrogen or a hydroxyl protecting group; and each R9 is hydrogen or a hydroxyl protecting group. The ketone compound of the formula VIII or the starting compound of the formula V may be produced by a method of oxidation of an alcohol compound of the formula Xl

in which R8 and R9 are hydroxyl protecting groups and n is 0 to 5 using an oxidising agent, preferably Dess-Martin periodinane. The alcohol starting compound of the formula Xl or VIII, as the case may be, may either be produced by wholly synthetic methods or, preferably, may be produced by hydrolysis of a naturally occurring EGC or EC compound as the case may be. In compounds of formula II, X and IX n is preferably 2 or 3. In the worked examples below we show that an amide is more hydrolytically stable than the analogous ester. The following examples illustrate the invention and support our hypothesis concerning the activity of

the amide compounds.

Example 1

DCM

10 Example 1A (-)-ECG-7TBS

To a solution of (-)-epicatechin gallate 1 (2.Og, 4.4mmol), in DMF (1OmL) at 0°C was added imidazole (3.Og, 0.044mol) followed by tert- butyldimethylsilyl chloride (6.6g, 0.044mol) and the mixture was allowed to warm to room temperature overnight. On completion of reaction the mixture was diluted with water (2OmL). The product was then partitioned between ether (2x 2OmL) and water (2OmL). The organics were then combined, dried with MgSO4, filtered and concentrated in vacuo to yield a colourless oil which was purified by flash chromatography (eluting with 5% Et2O: Pet Ether) to give the product 2 as a colourless oil, 5.Og, 91%; δH (400MHz, CDCI3) 0.08- 0.21 (m, 42H, 7x OSi(CH3)2C(CH3)3), 0.90- 0.98 (m, 63H, 7x OSi(CH3)2C(CH3)3), 2.97 (d, 2H, J 3.1 , ArCH2CHCHO), 5.05 (s, 1 H, ArCH2CHCHO), 5.56 (m, 1 H, ArCH2CHCHO), 5.96 (d, 1 H, J 2.3, ArH), 6.18 (d, 1 H, J 2.3, ArH), 6.74 (d, 1 H, J 8.7, ArH), 6.89 (d, 1 H, J 2.1 , ArH) 6.95 (dd, 1 H, J 8.3, 2.1 , ArH), 7.09 (s, 2H, 2x ArH); δc (100MHz, CDCI3) -4.4, -4.3, -4.2 -4.1 , -3.9, -3.7, 18.1 , 18.2, 18.3, 18.4, 18.8, 25.7, 25.8, 25.9, 26.1, 26.7, 68.0, 76.7, 101.7, 103.7, 103.9, 115.3, 119.3, 119.7, 120.8, 121.7, 131.1 , 142.9, 146.6, 148.2, 154.7, 154.9, 155.6, 165.0; MS (m/z) No mass ion observed; [α]D -57.9° (c 1.0, CHCI3, at 250C). Example 1B EC-4TBS-OH

To a solution of (-)-ECG-7TBS 2 (5g, 4.0mmol), in THF (20OmL) at 0°C was added a solution of lithium aluminium hydride in THF (1 M, 4.OmL) and the mixture was monitored by TLC. After 30 minutes the mixture was diluted with water (0.4mL) followed by the addition of 15% NaOH aq (0.4mL) followed by water (1.OmL) and the resulting precipitate was filtered through celite. The crude product was purified by flash chromatography (eluting with 5% Et2O: Pet Ether) to give the product 3 as a colourless oil, 2.4g, 80%; umax/ cm"1 2930; δH (400MHz, CDCI3) 0.20- 0.24 (m, 24H, 4x OSi(CH3)2C(CH3)3), 0.98 (s, 9H, OSi(CH3)2C(CH3)3), 0.99 (s, 9H, OSi(CH3)2C(CH3)3), 1.00 (s, 9H, OSi(CH3)2C(CH3)3), 1.02 (s, 9H, OSi(CH3)2C(CH3)3), 1.72 (d, 2H, J 6.2, ArCH2CHCHO), 2.89 (brd, 1 H, J 3.5, OH) 4.22- 4.24 (m, 1 H, ArCH2CHCHO), 4.90 (s, 1 H, ArCH2CHCHO), 5.99 (d, 1 H, J 2.3, ArH), 6.14 (d, 1 H, J 2.3, ArH), 6.86- 6.88 (m, 2H, 2x ArH), 6.94 (d, 1 H, J 2.0, ArH) 6.97- 6.98 (m, 2H, 2x ArH); δc (125MHz, CDCI3) -4.3, -4.0, -3.8, -3.7, 18.2, 18.3, 18.5, 18.8, 25.7, 25.8, 26.0, 26.3, 28.7, 66.1 , 78.1 , 101.6, 104.1 , 119.4, 121.1 , 131.3, 146.8, 147.0, 155.0, 155.1 , 155.5; MS (FAB, m/z) 747 (M+1 , 100%), 729 (M- 17, 55%); HRMS (FAB, m/z) found M 746.4221 , C39H70O6Si4 requires M 746.4250; [α]D -7.3° (c 1.0, CHCI3, at 250C). Example 1C

To a solution of alcohol 3 (1.Og, 1.3mmol), in DCM (1 OmL) at 00C was added Dess-Martin periodinane (620mg, 1.4mmol) and the mixture was monitored by TLC. After 9 hours the mixture partitioned between 1 M NaOH aq (1OmL) and DCM (2x 1OmL). The organics were then combined, washed with brine (2OmL), dried with MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash chromatography (eluting with 5% Et2O: Pet Ether) to give the product 4 as a colourless oil, 870mg, 91 %; umax/ cm"1 2928, 1508; δH (400MHz, CDCI3) 0.15- 0.25 (m, 24H1 4x OSi(CH3)2C(CH3)3), 0.96- 1.03 (m, 36H, 4x OSi(CH3)2C(CH3)3), 3.50 (d, 2H, J 2.3, ArCH2CHCHO), 5.26 (s, 1 H, ArCH2CHCHO), 6.07 (d, 1 H, J 2.2, ArH), 6.28 (d, 1 H, J 2.2, ArH), 6.81- 6.82 (m, 3H, 3x ArH); δc(125MHz, CDCI3) - 4.0, -3.9, -3.8, -3.7, 18.6, 18.8, 26.0, 26.1 , 26.3, 34.6, 83.3, 103.3, 105.3, 105.6, 119.8, 120.2, 121.4, 128.7, 147.4, 147.5, 154.4, 154.9, 156.2, 205.8; MS (FAB, m/z) 744 (M+1 , 100%), 368 (M-376, 98%); HRMS (FAB, m/z) found M 744.4127, C39H68O6Si4 requires M 744.4093; [α]D +24.0° (c 1.2, CH2Cl2, at 240C). Example 1D

To a solution of ketone 4 (500mg, 0.67mmol), in THF (1OmL) was added benzylamine (0.15mL, 1.3mmol) followed by acetic acid (3 drops) and the mixture was stirred for 30 minutes before the addition of sodium cyanoborohydride in THF (1 M, 0.74ml_). The mixture was then stirred at room temperature overnight. The product was partitioned between ether (2x 2OmL) and water (2OmL). The organics were then combined, dried with MgSO4, filtered and concentrated in vacuo to yield a yellow oil which was purified by flash chromatography (eluting with 10% Et2O: Pet Ether) to give the product 5 as a colourless oil, 250mg, 45%; umax/ cm"1 2955, 2930, 2858; δH (400MHz, CDCI3) 0.16- 0.27 (m, 24H, 4x OSi(CH3)2C(CH3)3), 0.99- 1.29 (m, 36H, 4x OSi(CH3)2C(CH3)3), 2.70 (dd, 1 H, J 17, 4.8, ArCH2CHCHO), 2.78 (dd, 1 H, J 17, 4.8, ArCH2CHCHO), 3.21- 3.23 (m, 1 H, ArCH2CHCHO), 3.71 (d, 1 H, J 14, NCH2Ar), 3.83 (d, 1 H1 J 14, NCH2Ar), 5.09 (d, 1 H, J 2.2, ArCH2CHCHO), 5.99 (d, 1 H, J 2.3, ArH), 6.14 (d, 1 H, J 2.3, ArH), 6.84- 6.93 (m, 3H, 3x ArH), 7.12- 7.28 (m, 5H, 5x ArH); δc (125MHz1 CDCI3) -3.9, -3.8, - 3.7, -3.6, 18.6, 18.7, 18.9, 25.3, 26.2, 26.3, 26.4, 51.4, 53.1 , 78.7, 101.8, 104.0, 105.6, 119.6, 119.7, 121.2, 127.1 , 128.3, 128.6, 132.5, 146.6, 147.1 , 155.2, 156.1 ; MS (FAB, m/z) 836 (M+1 , 75%), 484 (M-351 , 100%); HRMS (FAB, m/z) found M 836.4991 , C46H78NO5Si4 requires M 836.4957; [α]D -3.3° (C lO, CH2CI2, at 230C). Example 1E

5 6

To a solution of amine 5 (420mg, 0.51 mmol), in EtOH (1OmL) and 5% palladium on activated carbon (10mg) and the mixture was stirred vigorously under an atmosphere of hydrogen for 16 hours. The product was filtered through celite and concentrated in vacuo to yield a brown oil which was purified by flash chromatography (eluting with 20% Et2O: Pet Ether) to give the product 6 as a colourless oil, 380mg, 100%; umax/ cm'12956, 2929, 2858; δH (400MHz, CDCI3) 0.10- 0.39 (m, 24H, 4x OSi(CH3)2C(CH3)3), 1.02- 1.10 (s, 36H, 4x OSi(CH3)2C(CH3)3), 2.57- 2.63 (m, 2H, ArCH2CHCHO and NH2), 2.76- 2.80 (m, 1 H, NH2), 2.89 (dd, 1 H, J 16, 5.0, ArCH2CHCHO), 3.29- 3.31 (m, 1 H, ArCH2CHCHO), 5.17 (d, 1 H, J 2.7, ArCH2CHCHO), 6.06 (d, 1 H, J 2.3, ArH), 6.19 (d, 1 H, J 2.2, ArH), 6.88- 6.97 (m, 3H, 3x ArH); δc(125MHz, CDCI3) -4.0, -3.8, -3.7, 1.4, 18.6, 18.7, 18.8, 26.1 , 26.2, 26.3, 26.4, 42.1 , 54.3, 78.5, 101.8, 103.9, 105.9, 119.5, 119.8, 121.1 , 132.3, 146.6, 147.1 , 155.1 , 155.2 156.1; MS (FAB, m/z) 746 (M+1 , 15%), 644 (M-101, 15%); HRMS (FAB, m/z) found M 746.4450, C39H72NO5Si4 requires M 746.4409; [α]D -4.6° (c 4.0, CH2Cl2, at 250C). Example 1F

To a solution of protected gallic acid 7 (130mg, 0.29mmol), in DCM (5.OmL) was added DCC (64mg, 0.31 mmol) and DMAP (5mg) and the mixture was stirred for 20 minutes. Amine 6 (190mg, 0.26mmol) was then added in DCM (2.OmL) and the mixture was stirred at room temperature for 16 hours. The resulting precipitate was then filtered and the filtrate concentrated in vacuo to yield a yellow oil which was purified by flash chromatography (eluting with 20% Et2O: Pet Ether) to give the product 8 as a colourless oil, 210mg, 68%; umax/ cm"12954, 1582, 1508; δH (500MHz, CDCI3) 0.25- 0.38 (m, 24H, 4x OSi(CH3)2C(CH3)3), 1.04- 1.13 (m, 36H, 4x OSi(CH3)2C(CH3)3), 3.03 (dd, 1 H, J 17, 3.1 , ArCH2CHCHO), 3.09 (dd, 1 H, J 17, 5.1 , ArCH2CHCHO), 4.95- 4.97 (m, 1 H, ArCH2CHCHO), 5.16 (s, 2H, ArOCH2Ph), 5.17 (s, 4H, 2x ArOCH2Ph), 5.20 (s, 1 H, ArCH2CHCHO), 6.16 (d, 1 H, J 2.3, ArH), 6.19 (d, 1 H, J 8.4, NH), 6.34 (d, 1 H, J 2.2, ArH), 6.93- 7.02 (m, 5H, 5x ArH) 7.37- 7.52 (m, 15H, 15x ArH); δc(125MHz, CDCI3) - 4.2, -4.1 , -4.0, 18.3, 18.4, 18.5, 25.8, 25.9, 26.0, 46.2, 71.3, 75.2, 101.8, 104.6, 105.0, 106.9, 118.8, 118.9, 119.2, 121.0, 127.6, 127.7, 128.0, 128.1 , 128.3, 128.6, 128.7, 130.1 , 131.0, 136.7, 137.5, 141.2, 146.7, 152.7, 155.2, 155.3, 155.5, 166.7; MS (El, m/z) 1169 (M+1 , 50%), 735 (M-433, 100%); HRMS (El, m/z) found M 1168.5817, C67H94NO9Si4 requires M 1168.6006; [α]D -12.3° (c 0.2, CHCI3, at 280C). Example 1G

8 9

To a solution of amide 8 (210mg, 0.18mmol), in EtOH (5.OmL) and 5% palladium on activated carbon (5.0mg) and the mixture was stirred vigorously under an atmosphere of hydrogen for 16 hours. The product was filtered through celite and concentrated in vacuo to yield a colourless oil which was purified by flash chromatography (eluting with 30% Et2O: Pet Ether) to give the product 9 as a colourless oil, 130mg, 80%; umax/ cm"13339, 2930, 2858, 1613, 1514; δH (500MHz, CDCI3) 0.21- 0.34 (m, 24H1 4x OSi(CH3)2C(CH3)3), 0.99- 1.11 (m, 36H, 4x OSi(CH3)2C(CH3)3), 2.96 (dd, 1 H, J 17, 2.5, ArCH2CHCHO), 3.11 (dd, 1 H, J 17, 5.5, ArCH2CHCHO), 4.74- 4.76 (m, 1 H, ArCH2CHCHO), 5.17 (s, 1 H, ArCH2CHCHO), 6.10 (d, 1 H, J 2.2, ArH), 6.28 (d, 1 H, J 2.2, ArH), 6.40 (d, 1 H, J 8.7, NH), 6.76- 7.17 (m, 5H, 5x ArH); δc(125MHz, CDCI3) -4.3, -4.2, 18.3, 18.5, 25.8, 26.0, 46.9, 65.9, 76.8, 101.8, 104.1 , 104.5, 106.9, 118.6, 118.7, 121.2, 124.8, 131.0, 135.7, 144.3, 146.7, 147.1 , 155.1 , 155.3, 155.4 168.4; MS (El, m/z) 898 (M+1 , 80%), 454 (M-444, 100%); HRMS (El, m/z) found M 898.4568, C46H76NO9Si4 requires M 898.4597; [α]D -79.6° (c 2.5, CHCI3, at 280C).

Example 1H Amide derivative

To a solution of amide 9 (11 Omg, 0.13mmol), in THF (2.OmL) and pyridine (0.5ml_) and 00C was added HF. Py complex (0.5ml_). After 2 hours the reaction mixture was diluted with water (5ml_) and the product was extracted into EtOAc (2x 10mL). The organics were then combined, washed with saturated CuSO4 (5mL), dried with MgSO4, filtered and concentrated in vacuo to yield a pale yellow solid which was purified by flash chromatography (eluting with 70% Et2O: Pet Ether) to give the product 10 as a colourless oil 20mg, 40%; umax/ cm"13320, 1604, 1516; δH (500MHz, acetone) 2.87 (dd, 1 H, J 16, 4.5, ArCH2CHCHO), 3.01 (s superimposing dd, 2H, J 16, 5.2, NH and ArCH2CHCHO), 4.76- 4.79 (m, 1 H, ArCH2CHCHO), 5.27 (d, 1 H, J 1.8, ArCH2CHCHO), 6.06 (d, 1 H, J 2.2, ArH), 6.12 (d, 1 H, J 2.2, ArH), 6.82- 6.93 (m, 4H, 4x ArH), 7.06 (s, 1 H, ArH), 7.82 (brs, 7H, 7x OH); δc(125MHz, acetone) 25.5, 46.6, 77.2, 95.0, 95.8, 99.2, 106.6, 113.5, 114.9, 117.9, 125.7, 130.6, 136.0, 144.6, 144.8, 145.1 , 155.9, 156.7, 157.0, 166.2; MS (El, m/z) 442 (M+1 , 30%), 233 (M-208, 55%); HRMS (El, m/z) found M 442.1126, C22H20NO9 requires M 442.1138; [α]D -319.0° (c 0.2, CO(CH3)2 at 260C). Example 2 - Effect of compound of Example 1 on MIC of oxacillin for MRSA The compounds were assayed in the following way: Bacterial strains: S. aureus BB568 (COL-type strain that carries mecA and pT181) was provided by Professor B. Berger-Bachi. EMRSA-15 and EMRSA-16 were clinical isolates from the Royal Free Hospital, London. Antibacterial susceptibility testing: Minimum Inhibitory Concentration (MIC) was determined by both broth and agar dilution techniques. Broth MIC testing was performed in 96-well microtitre trays with an inoculum of about 104 cfu in 100 μl_ of Mueller-Hinton broth (MHB) (Oxoid, Basingstoke, United Kingdom) supplemented with 2% NaCI. MIC determinations by agar dilution were carried out using Mueller-Hinton agar (Oxoid) with an inoculum of about 104 organisms per spot. For both methods, MIC values were obtained after incubation at 350C for 24 h. S. aureus ATCC29213 was used as the standard. The assays yielded the following data: Table 1 - MIC of amide of example 1 and ECG in MHB + 2% NaCI at 35° C after 24 hrs incubation

Table 2 - Effect of combination of amide of Example 1 & ECG on MIC of Oxacillin for MRSA

o aMIC of Oxacillin was determined in the absence (-) or presence of each compound at indicated concentrations. Cell growth was assessed after incubation at 350C for 24h. Example 3 - Esterase resistance of compound of example 1 The product of example 1 was tested for in esterase sensitivity as 5 compared to ECG using commercially available porcine liver esterase (Sigma). ECG was totally hydrolysed to 10 min at 370C whereas the compound of example 1 was not affected in this time. Example 4 - Effect of ECg on protein export This example examines the capacity of ECg and the novel amide of o example 1 to modulate the export of proteins from S.aureus. S.aureus is grown in Mineller-Hinton broth containing various concentrates of ECg and amide of example 1. α-Toxin is detected in the growth medium by use of an anti-α-toxin antibody applied to exoproteins that are separated by SDS-PAGE and transferred to nitrocellulose membrane by electroblotting. The method will be 5 used to determine the effect on export of DNase, alpha toxin, protein A and secreted β-lactamase. it is expected that the amide, as does ECg1 will reduce the export of these proteins. Example 5 - Interaction of ECg and the staphylococcal membrane The above observations are compatible with the concept that the o compound exerts its effects through interaction with the cytoplasmic membrane of staphylococci, rather than through interaction with a specific target (such as peptidoglycan or the transcription regulatory system) on or within the bacterial

cell.

This example investigates the capacity of the compound of example 1

and ECg to bind to staphylococcal cells: as shown in Table 3, the binding of

ECg is enhanced by EC. It is expected that the binding of the amide of example

1 will be similarly enhanced. The method is based on Hashimoto, T. et al 1999.

Table 3: Influence of epicatechin (EC) on binding of epicatechin gallate (ECg)

to EMRSA-16 cells.

a Binding assessed by HPLC analysis of unbound catechin remaining in assay

medium after cell removal. Example 5

The steps to synthesise 12, 13, 16 and 18 were carried out as in Example 1 Compound 14 was isolated from the product mixture containing compound 13 by chromatography and it was present at a yield of 26%. To a solution of ketone 16 (500mg, 0.67mmol), in THF (1 OmL) was added benzylamine (0.15ml_, 1.3mmol) followed by acetic acid (3 drops) and the mixture was stirred for 30 minutes before the addition of sodium cyanoborohydride in THF (1 M, 0.74ml_). The mixture was then stirred at room temperature overnight. The product was partitioned between ether (2x 2OmL) and water (2OmL). The organics were then combined, dried with MgSO4, filtered and concentrated in vacuo to yield a yellow oil which was purified by flash chromatography (eluting with 10% Et2O: Pet Ether) to give: Product 17 as a colourless oil, 250mg, 45%; umax/ cm"1 2955, 2930, 2858; δH (400MHz, CDCI3) 0.16- 0.27 (m, 24H, 4x OSi(CH3)2C(CH3)3), 0.99- 1.29 (m, 36H, 4x OSi(CH3)2C(CH3)3), 2.70 (dd, 1 H1 J 17, 4.8, ArCH2CHCHO), 2.78 (dd, 1 H1 J 17, 4.8, ArCH2CHCHO), 3.21 - 3.23 (m, 1 H, ArCH2CHCHO), 3.71 (d, 1 H, J 14, NCH2Ar), 3.83 (d, 1 H, J 14, NCH2Ar), 5.09 (d, 1 H, J 2.2, ArCH2CHCHO), 5.99 (d, 1 H, J 2.3,ArH), 6.14 (d, 1 H, J 2.3, ArH), 6.84- 6.93 (m, 3H, 3x ArH), 7.12- 7.28 (m, 5H, 5x ArH); δc(125MHz, CDCI3) -3.9, -3.8, -3.7, -3.6, 18.6, 18.7, 18.9, 25.3, 26.2, 26.3, 26.4, 51.4, 53.1 , 78.7, 101.8, 104.0, 105.6, 119.6, 119.7, 121.2, 127.1 , 128.3, 128.6, 132.5, 146.6, 147.1 , 155.2, 156.1 ; MS (FAB, m/z) 836 (M+1 , 75%), 484 (M-351 , 100%); HRMS (FAB, m/z) found M 836.4991 , C46H78NO5Si4 requires M 836.4957; [α]D -3.3° (c 1.0, CH2CI2, at 230C). Product 18 as a colourless oil, 68mg, 26%; umax/ crrr1 2955, 2929, 2858; δH (400MHz, CDCI3) 0.18- 0.28 (m, 24H, 4x OSi(CH3)2C(CH3)3), 0.98- 1.06 (m, 36H, 4x OSi(CH3)2C(CH3)3), 2.50 (dd, 1 H, J 15, 8.5, ArCH2CHCHO), 2.96- 3.07 (m, 3H, ArCH2CHCHO and ArCH2CHCHO), 3.64 (d, 1 H, J 14, NCH2Ar), 3.83 (d, 1 H, J 14, NCH2Ar), 4.70 (d, 1 H, J 7.6, ArCH2CHCHO), 5.97 (d, 1 H, J 2.3, ArH), 6.10 (d, 1 H, J 2.4, ArH), 6.86- 6.90 (m, 3H, 3xArH), 7.15- 7.31 (m, 5H, 5xArH); δc (125MHz, CDCI3) -4.0, -3.8, -3.7, -3.6, 18.6, 18.7, 18.9, 26.0, 26.1 , 26.2, 26.4, 51.1, 54.8, 81.4, 101.7, 104.0, 106.0, 120.3, 120.6, 127.4, 128.3, 128.8, 132.5, 147.4, 154.8, 155.2, 156.1 ; MS (FAB, m/z) 836 (M+1 , 100%); HRMS (FAB, m/z) found M 836.4914, C46H78NO5Si4 requires M 836.4957; [α]D +40.7° (c 0.1 , CH2CI2, at 250C).

A solution of amine 17 (420mg, 0.51 mmol), was formed in EtOH (1OmL) and contacted with 5% palladium on activated carbon (10mg) and the mixture was stirred vigorously under an atmosphere of hydrogen for 16 hours. The product was filtered through celite and concentrated in vacuo to yield a brown oil which was purified by flash chromatography (eluting with 20% Et2O: Pet Ether) to give the product 19 as a colourless oil, 380mg, 100%; umax/ cm"12956, 2929, 2858; δH (400MHz, CDCI3) 0.10- 0.39 (m, 24H, 4x OSi(CH3)2C(CH3)3), 1.02- 1.10 (s, 36H, 4x OSi(CH3)2C(CH3)3), 2.57- 2.63 (m, 2H, ArCH2CHCHO and NH2), 2.76- 2.80 (m, 1 H, NH2), 2.89 (dd, 1 H, J 16, 5.0, ArCH2CHCHO), 3.29- 3.31 (m, 1 H1 ArCH2CHCHO)1 5.17 (d, 1 H, J 2.7, ArCH2CHCHO), 6.06 (d, 1 H, J 2.3, ArH), 6.19 (d, 1 H, J 2.2, ArH), 6.88- 6.97 (m, 3H, 3x ArH); δc (125MHz, CDCI3) -4.0, -3.8, -3.7, 1.4, 18.6, 18.7, 18.8, 26.1 , 26.2, 26.3, 26.4, 42.1 , 54.3, 78.5, 101.8, 103.9, 105.9, 119.5, 119.8, 121.1 , 132.3, 146.6, 147.1 , 155.1 , 155.2 156.1 ; MS (FAB, m/z) 746 (M+1 , 15%), 644 (M-101 , 15%); HRMS (FAB, m/z) found M 746.4450, C39H72NO5Si4 requires M 746.4488; [α]D -4.6° (c 4.0, CH2CI2, at 250C). Protected alcohol 14 was subjected to Dess-Martin Oxidation with periodinane in DCM at 00C, then oxidised further with NaO2CI in 2-methyl-2- butene and t-butanol in pH4 buffer at room temperature to form acid 15 at 58% yield.

To a solution of 15 (600mg, H mmol), in DCM (1 OmL) was added DCC (230mg, 1.1 mmol) and DMAP (5mg) and the mixture was stirred for 20 minutes. Amine 19 (670mg, 0.92mmol) was then added in DCM (5.OmL) and the mixture was stirred at room temperature for 16 hours. The resulting precipitate was then filtered and the filtrate concentrated in vacuo to yield a yellow oil which was purified by flash chromatography (eluting with 20% Et2O: Pet Ether) to give the product 20 as a colourless oil, 950mg, 83%, containing small aromatic impurity; umax/ cm"1 2956, 2930, 2858, 1669, 1473; δH (500MHz, CDCI3) 0.18- 0.31 (m, 42H, 7x OSi(CH3)2C(CH3)3), 0.99- 1.09 (m, 63H, 7x OSi(CH3)2C(CH3)3), 3.03- 3.04 (m, 2H, ArCH2CHCHO), 4.89- 4.91 (m, 1 H, ArCH2CHCHO), 5.18 (s, 1 H, ArCH2CHCHO), 6.09 (d, 1 H, J 2.3, ArH), 6.20 (d, 1 H, J 8.5, NH), 6.28 (d, 1 H, J 2.3, ArH), 6.82 (s, 2H, 2x ArH), 6.89 (d, 1 H, J 8.3, ArH), 6.98 (d, 1 H1 J 2.1 , ArH), 7.04 (dd, 1 H, J 8.3, 2.2, ArH); δc(100MHz, CDCI3) -3.9. -3.8, -3.7, -3.5, -3.4, -3.3, -3.2, 18.6, 18.7, 18.8, 19.0, 19.2, 26.1 , 26.3, 26.5, 26.6, 28.0, 46.3, 77.7, 102.0, 104.9, 105.2, 108.9, 113.2, 116.4, 117.0, 119.1 , 119.2, 120.9, 121.3, 125.2, 126.9, 129.0, 129.3, 131.4, 141.9, 144.0, 146.4, 146.9, 147.3, 148.8, 149.7, 155.5, 155.6, 155.8, 162.8, 166.6; MS (El, m/z) 898 (M+1 , 80%), 454 (M-444, 100%); HRMS (El, m/z) found M not obtained; [α]D -23.1° (c 2.5, CHCI3, at 280C). To a solution of amide 20 (110mg, 0.13mmol), in THF (2.OmL) and pyridine (0.5ml_) and 0°C was added HF. Py complex (0.5mL). After 2 hours the reaction mixture was diluted with water (5mL) and the product was extracted into EtOAc (2x 1OmL). The organics were then combined, washed with 5 saturated CuSO4 (5mL), dried with MgSO4, filtered and concentrated in vacuo to yield a pale yellow solid which was purified by flash chromatography (eluting with 70% Et2O: Pet Ether) to give the product 21 as a colourless oil 20mg, 40%; umax/ cm"13320, 1604, 1516; δH (500MHz, acetone) 2.87 (dd, 1 H, J 16, 4.5, ArCH2CHCHO), 3.01 (s superimposing dd, 2H, J 16, 5.2, NH and o ArCH2CHCHO), 4.76- 4.79 (m, 1 H, ArCH2CHCHO), 5.27 (d, 1 H, J 1.8, ArCH2CHCHO), 6.06 (d, 1 H, J 2.2, ArH), 6.12 (d, 1 H, J 2.2, ArH), 6.82- 6.93 (m, 4H, 4x ArH), 7.06 (s, 1 H, ArH), 7.82 (brs, 7H, 7x OH); δc(125MHz, acetone) 25.5, 46.6, 77.2, 95.0, 95.8, 99.2, 106.6, 113.5, 114.9, 117.9, 125.7, 130.6, 136.0, 144.6, 144.8, 145.1 , 155.9, 156.7, 157.0, 166.2; MS (El1 m/z) 442 (M+1 , 5 30%), 233 (M-208, 55%); HRMS (El, m/z) found M 442.1126, C22H20NO9 requires M 442.1138; [α]D -319.0° (c 0.2, CO(CH3)2 at 260C).

A solution of amine 18 (100mg, 0.12mmol), was formed in EtOH (1OmL) and contacted with 5% palladium on activated carbon (5.0mg) and the mixture was stirred vigorously under an atmosphere of hydrogen for 16 hours. The o product was filtered through celite and concentrated in vacuo to yield a yellow oil which was purified by flash chromatography (eluting with 50% Et2O: Pet Ether) to give the product 22 as a colourless oil, 80mg, 91 %; umax/ cm"1 2956, 2929, 2858; δH (400MHz, CDCI3) 0.26- 0.32 (m, 24H, 4x OSi(CH3)2C(CH3)3), 1.05 (s, 9H1 OSi(CH3)2C(CH3)3), 1.06 (s, 9H, OSi(CH3)2C(CH3)3), 1.08 (s, 9H, 5 OSi(CH3)2C(CH3)3), 1.09 (s, 9H, OSi(CH3)2C(CH3)3), 1.41 (brs, 2H, NH2), 2.45 (dd, 1 H1 J 16, 9.8, ArCH2CHCHO), 3.05 (dd, 1 H, J 16, 5.4, ArCH2CHCHO), 3.24- 3.29 (m, 1 H, ArCH2CHCHO), 4.49 (d, 1 H, J 6.8, ArCH2CHCHO), 6.06 (d, 1 H, J 2.2, ArH), 6.20 (d, 1 H, J 2.3, ArH), 6.94- 7.01 (m, 3H, 3x ArH); δc (125MHz, CDCI3) -4.0, -3.9, -3.7, -3.6, 18.6, 18.7, 18.8, 18.9, 26.1 , 26.2, 26.3, 0 26.6, 41.4, 56.0, 81.2, 101.7, 104.1 , 106.0, 120.2, 120.7, 121.6, 132.4, 147.4, 154.9, 155.2156.1 ; MS (FAB, m/z) 746 (M+1 , 20%), 367 (M-378, 100%); HRMS (FAB, m/z) found M 746.4568, C39H72NO5Si4 requires M 746.4488; [α]D +14.4° (c 4.0, CH2CI2, at 250C).

Protected alcohol 14 was subjected to Dess-Martin Oxidation with periodinane in DCM at 00C, then oxidised further with NaO2CI in 2-methyl-2- 5 butene and t-butanol in pH4 buffer at room temperature to form acid 15 at 58% yield. To a solution of 15 (90mg, 0.20mmol), in DCM (5.OmL) was added DCC (42mg, 0.20mmol) and DMAP (5mg) and the mixture was stirred for 20 minutes. Amine 22 (1 OOmg, 0.13mmol) was then added in DCM (2.OmL) and the mixture l o was stirred at room temperature for 16 hours. The resulting precipitate was then filtered and the filtrate concentrated in vacuo to yield a yellow oil which was purified by flash chromatography (eluting with 30% Et2O: Pet Ether) to give the product 23 as a colourless oil, 90mg, 59%; umax/ cm'1 2929, 2858, 1582; δH (400MHz, CDCI3) 0.09- 0.26 (m, 24H, 4x OSi(CH3)2C(CH3)3), 0.84 (s, 9H, 15 OSi(CH3)2C(CH3)3), 0.98 (s, 9H, OSi(CH3)2C(CH3)3), 1.00 (s, 9H, OSi(CH3)2C(CH3)3), 1.02 (s, 9H, OSi(CH3)2C(CH3)3), 2.53 (dd, 1H, J 17, 5.0, ArCH2CHCHO), 2.70 (dd, 1 H, J 17, 2.1 , ArCH2CHCHO), 4.72- 4.76 (m, 1 H, ArCH2CHCHO), 5.30 (d, 1 H, J 3.0, ArCH2CHCHO), 6.03 (d, 1 H, J 2.3, ArH), 6.19 (d, 1 H, J 8.4, NH), 6.26 (d, 1 H, J 2.3, ArH), 6.84- 6.85 (m, 3H, 3x ArH), 20 6.99 (S, 2H, 2xArH),; δc(125MHz, CDCI3) -4.4, -4.3, -4.2, -4.1 , 18.3, 18.5, 22.1 , 25.7, 25.8, 25.9, 46.9, 71.5, 75.2, 78.0, 101.4, 103.9, 104.1 , 107.1, 118.2, 118.4, 121.2, 127.6, 128.1 , 128.2, 128.6, 129.9, 132.3, 136.7, 137.5, 141.4, 147.0, 152.7, 154.6, 155.1 , 155.5, 166.7; MS (EI, m/z) 1190 (M+Na, 50%), 589 (M-578, 100%); HRMS (El, m/z) found M 1190.5826, C67H93NO9NaSi4 requires 25 M 1190.5825.

To a solution of amide 23 (100mg, O.H mmol), in THF (2.OmL) and pyridine (0.5mL) at 0°C was added HF. Py complex (0.5mL). After 2 hours the reaction mixture was diluted with water (5mL) and the product was extracted into EtOAc (2x 1OmL). The organics were then combined, washed with 3 o saturated CuSO4 (5mL), dried with MgSO4, filtered and concentrated in vacuo to yield a pale yellow solid which was purified by flash chromatography (eluting with 70% Et2O: Pet Ether) to give the product 24 as a colourless oil 20mg, 45%; umax/ cm"1 3275, 1521 ; δH (500MHz, acetone) 2.77 (dd, 1 H, J 16, 3.3, ArCH2CHCHO), 2.94 (dd, 1 H1 J 16, 5.5, ArCH2CHCHO), 4.56- 4.62 (m, 1 H, ArCH2CHCHO), 5.10 (d, 1 H, J 7.7, ArCH2CHCHO), 5.97 (d, 1 H, J 2.2, ArH), 6.09 (d, 1 H, J 2.2, ArH), 6.79- 6.92 (m, 4H, 4x ArH)1 7.00 (d, 1 H, J 2.0, ArH), 7.39 (d, 1 H, J 8.4, NH), 7.77- 7.79 (m, 2H, 2x OH)1 8.00- 8.09 (m, 3H1 3x OH)1 8.25 (S1 1 H1 OH); δc (125MHz1 acetone) 25.0, 47.7, 79.4, 94.7, 95.4, 99.6, 106.7, 114.0, 118.9, 144.8, 145.1 , 155.9, 156.4, 157.0; MS not obtained, several techniques attempted; [α]D +32.1° (c 1.0, CO(CH3)2 at 230C).

Example 6

To a solution of tri-O-Bn gallic acid (90mg, 0.20mmol), in DCM (5.OmL) was added DCC (42mg, 0.20mmol) and DMAP (5mg) and the mixture was stirred for 20 minutes. Amine 22 synthesised as in example above (100mg, 0.13mmol) was then added in DCM (2.OmL) and the mixture was stirred at room temperature for 16 hours. The resulting precipitate was then filtered and the filtrate concentrated in vacuo to yield a yellow oil which was purified by flash chromatography (eluting with 30% Et2O: Pet Ether) to give the product 27 as a colourless oil, 90mg, 59%; umax/ cm"1 2929, 2858, 1582; δH (400MHz1 CDCI3) 0.09- 0.26 (m, 24H1 4x OSi(CH3)2C(CH3)3), 0.84 (s, 9H, OSi(CH3)2C(CH3)3), 0.98 (S1 9H, OSi(CH3)2C(CH3)3), 1.00 (s, 9H1 OSi(CH3)2C(CH3)3), 1.02 (s, 9H1 OSi(CH3)2C(CH3)3), 2.53 (dd, 1 H, J 17, 5.0, ArCH2CHCHO)1 2.70 (dd, 1 H, J 17, 2.1 , ArCH2CHCHO)1 4.72- 4.76 (m, 1 H1 ArCH2CHCHO)1 5.11 (s, 2H1 OCH2Ph)1 5.12 (S1 4H1 2x OCH2Ph)1 5.30 (d, 1 H1 J 3.0, ArCH2CHCHO), 6.03 (d, 1 H1 J2.3, ArH)1 6.19 (d, 1 H1 J 8.4, NH)1 6.26 (d, 1 H1 J 2.3, ArH)1 6.84- 6.85 (m, 3H, 3x ArH), 6.99 (s, 2H, 2x ArH), 7.27- 7.42 (m, 15H, 15x ArH); δc (125MHz, CDCI3) -4.4, -4.3, -4.2, -4.1 , 18.3, 18.5, 22.1 , 25.7, 25.8, 25.9, 46.9, 71.5, 75.2, 78.0, 101.4, 103.9, 104.1 , 107.1 , 118.2, 118.4, 121.2, 127.6, 128.1 , 128.2, 128.6, 129.9, 132.3, 136.7, 137.5, 141.4, 147.0, 152.7, 154.6, 155.1 , 155.5, 166.7; MS (El, m/z) 1190 (M+Na, 50%), 589 (M-578, 100%); HRMS (El, m/z) found M 1190.5826, C67H93NO9NaSi4 requires M 1190.5825.

A solution of amide 27 (90mg, 0.77mmol) was formed in EtOH (5.OmL) and there was added 5% palladium on activated carbon (5.0mg) and the mixture was stirred vigorously under an atmosphere of hydrogen for 16 hours. The product was filtered through celite and concentrated in vacuo to yield a colourless oil which was purified by flash chromatography (eluting with 30% Et2O: Pet Ether) to give the product 28 as a colourless oil, 48mg, 69%; umax/ cm" 1 3371 , 2956, 2930, 2858; δH (400MHz, CDCI3) 0.04- 0.26 (m, 24H, 4x OSi(CH3)2C(CH3)3), 0.89- 1.02 (m, 36H, 4x OSi(CH3)2C(CH3)3), 2.12 (brs, 1 H, OH), 2.55 (dd, 1 H, J 17, 5.1 , ArCH2CHCHO), 2.71 (dd, 1 H, J 17, 2.7, ArCH2CHCHO), 4.67- 4.73 (m, 1 H, ArCH2CHCHO), 5.30 (d, 1 H, J 3.3, ArCH2CHCHO), 6.01 (d, 1 H, J 2.3, ArH), 6.23 (d, 1 H, J 2.3, ArH), 6.47 (d, 1 H, J 8.3, NH), 6.79- 6.82 (m, 2H, 2x ArH), 6.90 (s, 2H, 2x ArH), 7.27 (brs, 2H, 2x OH); δc (100MHz, CDCI3) -3.9, -3.8, -3.7, -2.5, 18.6, 18.8, 26.1 , 26.3, 47.7, 78.3, 101.8, 103.8, 104.4, 107.5, 118.5, 118.8, 121.6, 125.2, 132.5, 136.1 , 144.7, 146.7, 147.4, 154.8, 155.4, 155.9, 168.7; MS (El, m/z) 920 (M+Na, 25%), 898 (M+1 , 100%); HRMS (El, m/z) found M 898.4521 , C46H76NO9Si4 requires M 898.4512; [α]D +4.4° (c 5.3, CHCI3, at 280C). Example 7 With the amide derivatives (21 and 24) in hand, their efficacy as modulators for β-lactam resistance in S. aureus was evaluated by determining their capcity to reduce the minimum inhibitory concentration (MIC) of oxacillin against MRSA strains BB 568, EMRSA-15 and EMRSA-16 as described in example 2. The galloyl amides 21 and 24 possessed extremely weak intrinsic antibacterial activity against three MRSA strains: BB 568 and the two epidemic strains EMRSA-15 and EMRSA-16 (MIC mg/L, Table 4). This level of activity was comparable to that found with ECg. Sub-inhibitory concentrations (25 mg/L) of 21 were able to reduce the resistance to oxacillin of all three strains examined (oxacillin MIC mg/L, Table 4). In particular, oxacillin against BB 568 by 21 (from 256 mg/L to 4-8 mg/L) was less than that observed with ECg, but represented a very large diminution of sensitivity. Compound 24 was less effective that 21 with regard to its capacity to modify the sensitivity to oxacillin of BB 568 and EMRSA-16, although a significant degree of sensitisation was observed with MRSA-15 (Table 4). The results show that sub-inhibitory concentrations (25mg/L) of the amide analogue 21 possessing the natural C-3 stereochemistry, was able to reduce the resistance of three strains of methicillin resistant S. aureus (BB 568, EMRSA-15 and EMRSA-16) to oxacillin comparable to levels achieved with ECg. The higher activity of amide 21 , compared to amide 24 indicates that carbonyl derived linkers demonstrating the natural 3R stereochemistry may provide compounds for improved sensitisation of MRSA isolates to a wide spectrum of β-lactam antibiotics.

Table 4. Antibacterial activity of ECg 21 and 24 and in combination with oxacillin against methicillin resistant Staphylococcus aureus (MRSA) strains

b results for 2 separate experiments given References Cartula, N, Vera-Samper, E, Villalain, J, Reyes Mateo, C & Micol, V. (2003) The relationship between the antioxidant and the antibacterial properties of glloylated catechins and the structure of phospholipid model membranes. Free Rad. Biol. Med. 34:648-662 Hamilton-Miller, JMT & Shah, S. (1999) Disorganization of cell division of methicillin-resistant Staphylococcus aureus by a component of tea (Camellia sinensis): a study by electron microscopy. FEMS Microbiol. Lett. 176:463-469. Hashimoto, T, Kumazawa, S, Nanjo, F, Hara, Y & Nakayama, T. (1999) Interaction of tea catechins with lipid bilayers investigated with liposome systems. Biosci. Biotechnol. Biochem. 63:2252-2255. Kajiya, K, Kumazawa, S & Nakayama, T. (2001) Steric effects on interaction of tea catechins with lipid bilayers. Biosci. Biotechnol. Biochem. 65:2638-2643. Kajiya, K, Kumazawa, S & Nakayama, T. (2002) Effects of external factors on the interaction of tea catechins with lipid bilayers. Biosci. Biotechnol. Biochem. 66:2330-2335. Nakayama, T, Ono, K & Hashimoto, K. (1998) Affinity of antioxidative polyphenols for lipid bilayers evaluated with a liposme system. Biosci. Biotechnol. Biochem. 62:1005-1007. Stapleton, PD & Taylor, PW. (2002) Methicillin resistance in Staphylococcus aureus: mechanisms and modulation. Sd. Progr. 85:57-72. Stapleton, PD, Shah, S, Anderson, JC, Hara, Y, Hamilton-Miller, JMT & Taylor, PW. (2004) Modulation of β-lactam resistance in Staphylococcus aureus by catechins and gallates. Int. J. Antimicrob. Agents, 2315), 462-7. Yam, TS, Shah, S & Hamilton-Miller, JMT. (1997) Microbiological activity of whole and fractionated crude extracts of tea (Camellia sinensis), and of tea components. FEMS Microbiol. Lett. 152:169-174. Yam, TS, Hamilton-Miller, JMT & Shah, S. (1998) The effect of a component of tea (Camellia sinensis) on methicillin resistance, PBP2' synthesis, and β-lactamase production in Staphylococcus aureus. J. Antimicrob. Chemother. 42:211-216. Yamashita, S., Yokoma, K., Matsumiya, N. & Yamaguchi, H. (2001 ) Successful green tea nebulization therapy for subglottic tracheal stenosis due to MRSA infection, J. Infect, 42, 222-223.

Previous Patent: GLYCOSYLATION OF ANTIBIOTICS

Next Patent: REGULATION CIRCUITS, DEVICES AND METHODS